1. [18F]-Fluorodeoxyglucose PET Imaging of Atherosclerosis
- Author
-
Poul Flemming Høilund-Carlsen and Björn A. Blomberg
- Subjects
medicine.medical_specialty ,Drug trial ,atherosclerosis *diagnostic use human image enhancement patient positioning positron emission tomography *procedures *scintiscanning fluorodeoxyglucose f 18 radiopharmaceutical agent ,F-fluorodeoxyglucose ,Fluorodeoxyglucose PET ,Fluorodeoxyglucose F18 ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Arterial inflammation ,Myocardial infarction ,Arterial Inflammation ,Atherosclerosis/diagnostic imaging ,Radiation ,business.industry ,Surrogate endpoint ,General Medicine ,Atherosclerosis ,Positron-Emission Tomography/methods ,medicine.disease ,PET ,Patient Positioning/methods ,18 f fluorodeoxyglucose ,Radiology ,Radiopharmaceuticals ,Image Enhancement/methods ,business ,Plaque inflammation - Abstract
[(18)F]-fluorodeoxyglucose PET ((18)FDG PET) imaging has emerged as a promising tool for assessment of atherosclerosis. By targeting atherosclerotic plaque glycolysis, a marker for plaque inflammation and hypoxia, (18)FDG PET can assess plaque vulnerability and potentially predict risk of atherosclerosis-related disease, such as stroke and myocardial infarction. With excellent reproducibility, (18)FDG PET can be a surrogate end point in clinical drug trials, improving trial efficiency. This article summarizes key findings in the literature, discusses limitations of (18)FDG PET imaging of atherosclerosis, and reports recommendations to optimize imaging protocols.
- Published
- 2015